Implementing parity for mental health and substance use treatment in Medicaid-Reference-Cited by-同舟云学术

Implementing parity for mental health and substance use treatment in Medicaid

Published:2020-06-23 Issue:4 Volume:55 Page:604-614
ISSN:0017-9124
Container-title:Health Services Research
language:en
Short-container-title:Health Serv Res

Author:

Burns Marguerite E.¹^ORCID,Dague Laura²,Saloner Brendan³,Voskuil Kristen⁴,Kim Nam Hyo⁵^ORCID,Serna Borrero Natalia⁶,Look Kevin⁷

Affiliation:

1. School of Medicine and Public Health University of Wisconsin‐Madison Madison Wisconsin

2. Texas A&M University College Station Texas

3. Health Policy and Management Johns Hopkins Bloomberg School of Public Health Baltimore Maryland

4. Institute for Research on Poverty University of Wisconsin‐Madison Madison Wisconsin

5. School of Pharmacy University of Wisconsin‐Madison Madison Wisconsin

6. University of Wisconsin‐Madison Madison Wisconsin

7. Social & Administrative Sciences School of Pharmacy University of Wisconsin‐Madison Madison Wisconsin

Funder

Wisconsin Department of Health Services

Publisher

Wiley

Subject

Health Policy

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/1475-6773.13309

Reference54 articles.

1. Mental and Substance Use Disorders Among Medicaid Recipients: Prevalence Estimates from Two National Surveys

2. U.S. Substance Abuse and Mental Health Services Administration.Results from the 2013 National Survey on Drug Use and Health: Mental Health Detailed Tables. Rockville MD.2014.https://www.samhsa.gov/data/sites/default/files/NSDUHresultsPDFWHTML2013/Web/NSDUHresults2013.pdf. Accessed September 4 2019.

3. GelenbergAJ FreemanMP MarkowitzJC et al.Practice guideline for the treatment of patients with major depressive disorder. American Psychiatric Association.2010.http://www.psychiatryonline.com/pracGuide/pracGuideTopic_7.aspx. Accessed May 17 2011.

4. Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders

5. Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial